A new George Church startup raises $16M. The first-time founders have a ‘crazy vision’ to bring ML to cell therapy
By her own admission, Elizabeth Wood is far from a typical biotech CEO.
Fittingly, she’s building an unconventional startup in JURA Bio, which announced on Thursday a $16.1 million seed round to bring machine learning into developing cell therapies. Wood co-founded JURA back in 2017 alongside Julie Norville, an MIT bioengineering PhD who is JURA’s chief technology officer.
The Harvard biologist George Church is also a founder, telling Endpoints News he expects JURA to play a role in an “amazing revolution” that applies machine learning to complex libraries of drug candidates. He says JURA is one of six biotechs he has founded around that theme. Others include Shape Therapeutics for RNA editing, Dyno Therapeutics on optimizing AAV vectors, Nabla Bio for designing antibodies, and Manifold Bio for protein therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.